Value of FDG-PET scans of non-demented patients in predicting rates of future cognitive and functional decline
Purpose The aim of this study was to examine the value of fluorodeoxyglucose (FDG) positron emission tomography (PET) in predicting subsequent rates of functional and cognitive decline among subjects considered cognitively normal (CN) or clinically diagnosed with mild cognitive impairment (MCI). Met...
Gespeichert in:
| Veröffentlicht in: | European journal of nuclear medicine and molecular imaging 2017-08, Vol.44 (8), p.1355-1363 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1363 |
|---|---|
| container_issue | 8 |
| container_start_page | 1355 |
| container_title | European journal of nuclear medicine and molecular imaging |
| container_volume | 44 |
| creator | Torosyan, Nare Mason, Kelsey Dahlbom, Magnus Silverman, Daniel H. S. |
| description | Purpose
The aim of this study was to examine the value of fluorodeoxyglucose (FDG) positron emission tomography (PET) in predicting subsequent rates of functional and cognitive decline among subjects considered cognitively normal (CN) or clinically diagnosed with mild cognitive impairment (MCI).
Methods
Analyses of 276 subjects, 92 CN subjects and 184 with MCI, who were enrolled in the Alzheimer’s Disease Neuroimaging Initiative, were conducted. Functional decline was assessed using scores on the Functional Activities Questionnaire (FAQ) obtained over a period of 36 months, while cognitive decline was determined using the Alzheimer’s disease Assessment Scale-Cognitive subscale (ADAS-Cog) and Mini-Mental State Examination (MMSE) scores. PET images were analyzed using clinically routine brain quantification software. A dementia prognosis index (DPI), derived from a ratio of uptake values in regions of interest known to be hypometabolic in Alzheimer’s disease to regions known to be stable, was generated for each baseline FDG-PET scan. The DPI was correlated with change in scores on the neuropsychological examinations to examine the predictive value of baseline FDG-PET.
Results
DPI powerfully predicted rate of functional decline among MCI patients (t = 5.75,
p
|
| doi_str_mv | 10.1007/s00259-017-3634-3 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1880468141</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1909109974</sourcerecordid><originalsourceid>FETCH-LOGICAL-c420t-5ae074205119dc3c0b203413417f37dfbe9e5d498dc71c11e232bac5ef7841963</originalsourceid><addsrcrecordid>eNp1kU9r3DAQxUVpyZ9tPkAuQdBLLmpnLHslHUOapIVAekh7FVppvCh45a1kF_rto82moQQCAj1mfvMk5jF2ivAZAdSXAtB0RgAqIZeyFfIdO8IlGqFAm_cvWsEhOy7lAQB1o80BO2y0lGg6ecTSLzfMxMeeX3-9ET-u7nnxLpVdIY1JBNpQmijwrZtiVYXHxLeZQvRTTGue3URPcD9Pcybux3WKU_xD3KVQi6liY3IDD-SHmOgj-9C7odDJ871gP6-v7i-_idu7m--XF7fCtw1MonMEqqoO0QQvPawakC3Wo3qpQr8iQ11ojQ5eoUekRjYr5zvqlW7RLOWCne99t3n8PVOZ7CYWT8PgEo1zsag1tEuN1XPBPr1CH8Y51z9XyoBBMEa1lcI95fNYSqbebnPcuPzXIthdGHYfhq1h2F0YVtaZs2fnebWh8DLxb_sVaPZAqa20pvzf02-6PgK0f5OU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1909109974</pqid></control><display><type>article</type><title>Value of FDG-PET scans of non-demented patients in predicting rates of future cognitive and functional decline</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Torosyan, Nare ; Mason, Kelsey ; Dahlbom, Magnus ; Silverman, Daniel H. S.</creator><creatorcontrib>Torosyan, Nare ; Mason, Kelsey ; Dahlbom, Magnus ; Silverman, Daniel H. S. ; Alzheimer’sDisease Neuroimaging Initiative ; the Alzheimer’sDisease Neuroimaging Initiative</creatorcontrib><description><![CDATA[Purpose
The aim of this study was to examine the value of fluorodeoxyglucose (FDG) positron emission tomography (PET) in predicting subsequent rates of functional and cognitive decline among subjects considered cognitively normal (CN) or clinically diagnosed with mild cognitive impairment (MCI).
Methods
Analyses of 276 subjects, 92 CN subjects and 184 with MCI, who were enrolled in the Alzheimer’s Disease Neuroimaging Initiative, were conducted. Functional decline was assessed using scores on the Functional Activities Questionnaire (FAQ) obtained over a period of 36 months, while cognitive decline was determined using the Alzheimer’s disease Assessment Scale-Cognitive subscale (ADAS-Cog) and Mini-Mental State Examination (MMSE) scores. PET images were analyzed using clinically routine brain quantification software. A dementia prognosis index (DPI), derived from a ratio of uptake values in regions of interest known to be hypometabolic in Alzheimer’s disease to regions known to be stable, was generated for each baseline FDG-PET scan. The DPI was correlated with change in scores on the neuropsychological examinations to examine the predictive value of baseline FDG-PET.
Results
DPI powerfully predicted rate of functional decline among MCI patients (t = 5.75,
p
< 1.0E-8) and pooled N + MCI patient groups (t = 7.02,
p
< 1.0E-11). Rate of cognitive decline on MMSE was also predicted by the DPI among MCI (t = 6.96,
p
< 1.0E-10) and pooled N + MCI (t = 8.78,
p
< 5.0E-16). Rate of cognitive decline on ADAS-cog was powerfully predicted by the DPI alone among N (
p
< 0.001), MCI (t = 6.46,
p
< 1.0E-9) and for pooled N + MCI (t = 8.85,
p
= 1.1E-16).
Conclusions
These findings suggest that an index, derivable from automated regional analysis of brain PET scans, can be used to help predict rates of functional and cognitive deterioration in the years following baseline PET.]]></description><identifier>ISSN: 1619-7070</identifier><identifier>EISSN: 1619-7089</identifier><identifier>DOI: 10.1007/s00259-017-3634-3</identifier><identifier>PMID: 28331953</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Aged ; Alzheimer's disease ; Automation ; Brain ; Cardiology ; Cognition ; Cognitive ability ; Cognitive Dysfunction - diagnostic imaging ; Cognitive Dysfunction - physiopathology ; Computer programs ; Correlation analysis ; Dementia ; Dementia disorders ; Emission analysis ; Female ; Fluorodeoxyglucose F18 ; Follow-Up Studies ; Functional anatomy ; Humans ; Imaging ; Impairment ; Male ; Medical imaging ; Medicine ; Medicine & Public Health ; Neurodegenerative diseases ; Neuroimaging ; Neurology ; Nuclear Medicine ; Oncology ; Original Article ; Orthopedics ; Patients ; Positron emission ; Positron emission tomography ; Prognosis ; Radiology ; Regional analysis ; Regional planning ; Software ; Tomography</subject><ispartof>European journal of nuclear medicine and molecular imaging, 2017-08, Vol.44 (8), p.1355-1363</ispartof><rights>Springer-Verlag Berlin Heidelberg 2017</rights><rights>European Journal of Nuclear Medicine and Molecular Imaging is a copyright of Springer, 2017.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c420t-5ae074205119dc3c0b203413417f37dfbe9e5d498dc71c11e232bac5ef7841963</citedby><cites>FETCH-LOGICAL-c420t-5ae074205119dc3c0b203413417f37dfbe9e5d498dc71c11e232bac5ef7841963</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00259-017-3634-3$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00259-017-3634-3$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28331953$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Torosyan, Nare</creatorcontrib><creatorcontrib>Mason, Kelsey</creatorcontrib><creatorcontrib>Dahlbom, Magnus</creatorcontrib><creatorcontrib>Silverman, Daniel H. S.</creatorcontrib><creatorcontrib>Alzheimer’sDisease Neuroimaging Initiative</creatorcontrib><creatorcontrib>the Alzheimer’sDisease Neuroimaging Initiative</creatorcontrib><title>Value of FDG-PET scans of non-demented patients in predicting rates of future cognitive and functional decline</title><title>European journal of nuclear medicine and molecular imaging</title><addtitle>Eur J Nucl Med Mol Imaging</addtitle><addtitle>Eur J Nucl Med Mol Imaging</addtitle><description><![CDATA[Purpose
The aim of this study was to examine the value of fluorodeoxyglucose (FDG) positron emission tomography (PET) in predicting subsequent rates of functional and cognitive decline among subjects considered cognitively normal (CN) or clinically diagnosed with mild cognitive impairment (MCI).
Methods
Analyses of 276 subjects, 92 CN subjects and 184 with MCI, who were enrolled in the Alzheimer’s Disease Neuroimaging Initiative, were conducted. Functional decline was assessed using scores on the Functional Activities Questionnaire (FAQ) obtained over a period of 36 months, while cognitive decline was determined using the Alzheimer’s disease Assessment Scale-Cognitive subscale (ADAS-Cog) and Mini-Mental State Examination (MMSE) scores. PET images were analyzed using clinically routine brain quantification software. A dementia prognosis index (DPI), derived from a ratio of uptake values in regions of interest known to be hypometabolic in Alzheimer’s disease to regions known to be stable, was generated for each baseline FDG-PET scan. The DPI was correlated with change in scores on the neuropsychological examinations to examine the predictive value of baseline FDG-PET.
Results
DPI powerfully predicted rate of functional decline among MCI patients (t = 5.75,
p
< 1.0E-8) and pooled N + MCI patient groups (t = 7.02,
p
< 1.0E-11). Rate of cognitive decline on MMSE was also predicted by the DPI among MCI (t = 6.96,
p
< 1.0E-10) and pooled N + MCI (t = 8.78,
p
< 5.0E-16). Rate of cognitive decline on ADAS-cog was powerfully predicted by the DPI alone among N (
p
< 0.001), MCI (t = 6.46,
p
< 1.0E-9) and for pooled N + MCI (t = 8.85,
p
= 1.1E-16).
Conclusions
These findings suggest that an index, derivable from automated regional analysis of brain PET scans, can be used to help predict rates of functional and cognitive deterioration in the years following baseline PET.]]></description><subject>Aged</subject><subject>Alzheimer's disease</subject><subject>Automation</subject><subject>Brain</subject><subject>Cardiology</subject><subject>Cognition</subject><subject>Cognitive ability</subject><subject>Cognitive Dysfunction - diagnostic imaging</subject><subject>Cognitive Dysfunction - physiopathology</subject><subject>Computer programs</subject><subject>Correlation analysis</subject><subject>Dementia</subject><subject>Dementia disorders</subject><subject>Emission analysis</subject><subject>Female</subject><subject>Fluorodeoxyglucose F18</subject><subject>Follow-Up Studies</subject><subject>Functional anatomy</subject><subject>Humans</subject><subject>Imaging</subject><subject>Impairment</subject><subject>Male</subject><subject>Medical imaging</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Neurodegenerative diseases</subject><subject>Neuroimaging</subject><subject>Neurology</subject><subject>Nuclear Medicine</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Orthopedics</subject><subject>Patients</subject><subject>Positron emission</subject><subject>Positron emission tomography</subject><subject>Prognosis</subject><subject>Radiology</subject><subject>Regional analysis</subject><subject>Regional planning</subject><subject>Software</subject><subject>Tomography</subject><issn>1619-7070</issn><issn>1619-7089</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kU9r3DAQxUVpyZ9tPkAuQdBLLmpnLHslHUOapIVAekh7FVppvCh45a1kF_rto82moQQCAj1mfvMk5jF2ivAZAdSXAtB0RgAqIZeyFfIdO8IlGqFAm_cvWsEhOy7lAQB1o80BO2y0lGg6ecTSLzfMxMeeX3-9ET-u7nnxLpVdIY1JBNpQmijwrZtiVYXHxLeZQvRTTGue3URPcD9Pcybux3WKU_xD3KVQi6liY3IDD-SHmOgj-9C7odDJ871gP6-v7i-_idu7m--XF7fCtw1MonMEqqoO0QQvPawakC3Wo3qpQr8iQ11ojQ5eoUekRjYr5zvqlW7RLOWCne99t3n8PVOZ7CYWT8PgEo1zsag1tEuN1XPBPr1CH8Y51z9XyoBBMEa1lcI95fNYSqbebnPcuPzXIthdGHYfhq1h2F0YVtaZs2fnebWh8DLxb_sVaPZAqa20pvzf02-6PgK0f5OU</recordid><startdate>20170801</startdate><enddate>20170801</enddate><creator>Torosyan, Nare</creator><creator>Mason, Kelsey</creator><creator>Dahlbom, Magnus</creator><creator>Silverman, Daniel H. S.</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20170801</creationdate><title>Value of FDG-PET scans of non-demented patients in predicting rates of future cognitive and functional decline</title><author>Torosyan, Nare ; Mason, Kelsey ; Dahlbom, Magnus ; Silverman, Daniel H. S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c420t-5ae074205119dc3c0b203413417f37dfbe9e5d498dc71c11e232bac5ef7841963</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Aged</topic><topic>Alzheimer's disease</topic><topic>Automation</topic><topic>Brain</topic><topic>Cardiology</topic><topic>Cognition</topic><topic>Cognitive ability</topic><topic>Cognitive Dysfunction - diagnostic imaging</topic><topic>Cognitive Dysfunction - physiopathology</topic><topic>Computer programs</topic><topic>Correlation analysis</topic><topic>Dementia</topic><topic>Dementia disorders</topic><topic>Emission analysis</topic><topic>Female</topic><topic>Fluorodeoxyglucose F18</topic><topic>Follow-Up Studies</topic><topic>Functional anatomy</topic><topic>Humans</topic><topic>Imaging</topic><topic>Impairment</topic><topic>Male</topic><topic>Medical imaging</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Neurodegenerative diseases</topic><topic>Neuroimaging</topic><topic>Neurology</topic><topic>Nuclear Medicine</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Orthopedics</topic><topic>Patients</topic><topic>Positron emission</topic><topic>Positron emission tomography</topic><topic>Prognosis</topic><topic>Radiology</topic><topic>Regional analysis</topic><topic>Regional planning</topic><topic>Software</topic><topic>Tomography</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Torosyan, Nare</creatorcontrib><creatorcontrib>Mason, Kelsey</creatorcontrib><creatorcontrib>Dahlbom, Magnus</creatorcontrib><creatorcontrib>Silverman, Daniel H. S.</creatorcontrib><creatorcontrib>Alzheimer’sDisease Neuroimaging Initiative</creatorcontrib><creatorcontrib>the Alzheimer’sDisease Neuroimaging Initiative</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of nuclear medicine and molecular imaging</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Torosyan, Nare</au><au>Mason, Kelsey</au><au>Dahlbom, Magnus</au><au>Silverman, Daniel H. S.</au><aucorp>Alzheimer’sDisease Neuroimaging Initiative</aucorp><aucorp>the Alzheimer’sDisease Neuroimaging Initiative</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Value of FDG-PET scans of non-demented patients in predicting rates of future cognitive and functional decline</atitle><jtitle>European journal of nuclear medicine and molecular imaging</jtitle><stitle>Eur J Nucl Med Mol Imaging</stitle><addtitle>Eur J Nucl Med Mol Imaging</addtitle><date>2017-08-01</date><risdate>2017</risdate><volume>44</volume><issue>8</issue><spage>1355</spage><epage>1363</epage><pages>1355-1363</pages><issn>1619-7070</issn><eissn>1619-7089</eissn><abstract><![CDATA[Purpose
The aim of this study was to examine the value of fluorodeoxyglucose (FDG) positron emission tomography (PET) in predicting subsequent rates of functional and cognitive decline among subjects considered cognitively normal (CN) or clinically diagnosed with mild cognitive impairment (MCI).
Methods
Analyses of 276 subjects, 92 CN subjects and 184 with MCI, who were enrolled in the Alzheimer’s Disease Neuroimaging Initiative, were conducted. Functional decline was assessed using scores on the Functional Activities Questionnaire (FAQ) obtained over a period of 36 months, while cognitive decline was determined using the Alzheimer’s disease Assessment Scale-Cognitive subscale (ADAS-Cog) and Mini-Mental State Examination (MMSE) scores. PET images were analyzed using clinically routine brain quantification software. A dementia prognosis index (DPI), derived from a ratio of uptake values in regions of interest known to be hypometabolic in Alzheimer’s disease to regions known to be stable, was generated for each baseline FDG-PET scan. The DPI was correlated with change in scores on the neuropsychological examinations to examine the predictive value of baseline FDG-PET.
Results
DPI powerfully predicted rate of functional decline among MCI patients (t = 5.75,
p
< 1.0E-8) and pooled N + MCI patient groups (t = 7.02,
p
< 1.0E-11). Rate of cognitive decline on MMSE was also predicted by the DPI among MCI (t = 6.96,
p
< 1.0E-10) and pooled N + MCI (t = 8.78,
p
< 5.0E-16). Rate of cognitive decline on ADAS-cog was powerfully predicted by the DPI alone among N (
p
< 0.001), MCI (t = 6.46,
p
< 1.0E-9) and for pooled N + MCI (t = 8.85,
p
= 1.1E-16).
Conclusions
These findings suggest that an index, derivable from automated regional analysis of brain PET scans, can be used to help predict rates of functional and cognitive deterioration in the years following baseline PET.]]></abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>28331953</pmid><doi>10.1007/s00259-017-3634-3</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1619-7070 |
| ispartof | European journal of nuclear medicine and molecular imaging, 2017-08, Vol.44 (8), p.1355-1363 |
| issn | 1619-7070 1619-7089 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1880468141 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Aged Alzheimer's disease Automation Brain Cardiology Cognition Cognitive ability Cognitive Dysfunction - diagnostic imaging Cognitive Dysfunction - physiopathology Computer programs Correlation analysis Dementia Dementia disorders Emission analysis Female Fluorodeoxyglucose F18 Follow-Up Studies Functional anatomy Humans Imaging Impairment Male Medical imaging Medicine Medicine & Public Health Neurodegenerative diseases Neuroimaging Neurology Nuclear Medicine Oncology Original Article Orthopedics Patients Positron emission Positron emission tomography Prognosis Radiology Regional analysis Regional planning Software Tomography |
| title | Value of FDG-PET scans of non-demented patients in predicting rates of future cognitive and functional decline |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T19%3A52%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Value%20of%20FDG-PET%20scans%20of%20non-demented%20patients%20in%20predicting%20rates%20of%20future%20cognitive%20and%20functional%20decline&rft.jtitle=European%20journal%20of%20nuclear%20medicine%20and%20molecular%20imaging&rft.au=Torosyan,%20Nare&rft.aucorp=Alzheimer%E2%80%99sDisease%20Neuroimaging%20Initiative&rft.date=2017-08-01&rft.volume=44&rft.issue=8&rft.spage=1355&rft.epage=1363&rft.pages=1355-1363&rft.issn=1619-7070&rft.eissn=1619-7089&rft_id=info:doi/10.1007/s00259-017-3634-3&rft_dat=%3Cproquest_cross%3E1909109974%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1909109974&rft_id=info:pmid/28331953&rfr_iscdi=true |